Loading institutional data...
Loading institutional data...
Insufficient data to determine institutional momentum.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $2.22 today, the market must believe free cash flow compounds -12.3%/yr for a decade (off $18M normalized FCF).
The market's -12.3% is more conservative than its 7-yr track record.
2-stage DCF · 0.04B shares · net debt -$3M
mean -7.0% · volatility σ 86% · implied rate exceeded in 4/6 yrs
Central path = implied -12.3%/yr growth; shaded band = ±1σ (86%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
No trend data available for this metric.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $120.5M 100.0% | $110.8M 100.0% | $117.1M 100.0% | $138.8M 100.0% | $139.6M 100.0% | $105.1M 100.0% | $64.4M 100.0% | $50.5M 100.0% | $31.8M 100.0% | $24.5M 100.0% |
| Research & Development | $6.4M 5.3% | $3.8M 3.4% | $4.7M 4.0% | $4.4M 3.2% | $4.4M 3.2% | $9.3M 8.9% | $871K 1.4% | $1.0M 2.0% | $1.1M 3.4% | $902K 3.7% |
| Selling, General & Admin | $18.4M 15.3% | $16.1M 14.5% | $21.5M 18.3% | $23.8M 17.2% | $24.3M 17.4% | $22.8M 21.7% | $17.9M 27.8% | $16.3M 32.2% | $11.7M 36.9% | $12.5M 50.9% |
| Total Operating Expenses | $109.2M 90.6% | $101.7M 91.8% | $164.2M 140.2% | $132.2M 95.2% | $136.1M 97.5% | $113.4M 107.9% | $64.4M 99.9% | $53.1M 105.0% | $36.3M 114.2% | $32.4M 132.3% |
| Operating Income | $11.3M 9.4% | $9.1M 8.2% | -$47.1M -40.2% | $6.6M 4.8% | $3.5M 2.5% | -$8.3M -7.9% | $67K 0.1% | -$2.5M -5.0% | -$4.5M -14.2% | -$7.9M -32.3% |
| Interest & Investment Income | $206K 0.2% | $88K 0.1% | $154K 0.1% | $41K 0.0% | $15K 0.0% | $42K 0.0% | $262K 0.4% | $101K 0.2% | $17K 0.1% | $36K 0.1% |
| Other Income (Expense), net | -$265K -0.2% | -$298K -0.3% | -$883K -0.8% | -$637K -0.5% | -$96K -0.1% | $7K 0.0% | -$625K -1.0% | $494K 1.0% | $332K 1.0% | -$53K -0.2% |
| Pretax Income | $11.0M 9.1% | $8.0M 7.2% | -$49.0M -41.9% | $5.6M 4.0% | $3.0M 2.1% | -$8.7M -8.3% | -$679K -1.1% | -$2.3M -4.5% | -$5.5M -17.3% | -$8.6M -35.1% |
| Income Tax Expense | $199K 0.2% | $160K 0.1% | -$364K -0.3% | $177K 0.1% | $157K 0.1% | $103K 0.1% | $193K 0.3% | -$157K -0.3% | $68K 0.2% | $197K 0.8% |
| Net Income | $11K 0.0% | $8K 0.0% | -$49K -0.0% | $5.4M 3.9% | $2.8M 2.0% | -$8.8M -8.4% | -$872K -1.4% | -$2.1M -4.2% | -$5.6M -17.5% | -$8.8M -35.9% |
| Per Share | ||||||||||
| EPS (Basic) | $0.10 | $-0.28 | $-4.11 | $-0.67 | $-0.77 | — | — | — | — | — |
| EPS (Diluted) | $0.10 | $-0.28 | $-4.11 | $-0.67 | — | — | — | — | — | — |
| Weighted Avg Shares (Basic) | 37.8M | 16.1M | 15.7M | 15.1M | 14.5M | — | — | — | — | — |
| Weighted Avg Shares (Diluted) | 38.0M | 16.1M | 15.7M | 15.1M | — | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
4/7 of the 9 checks — 2 couldn't be scored (see above), so the score is out of the 7 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $24M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 18%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $3M covers all $289617 of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2017-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 12-yr range · 60th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 12-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 2.8× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| R&D | 2.0 | 1.4 | 8.9 | 3.2 | 3.2 | 4.0 | 3.4 | 5.3 |
| SG&A | 32.2 | 27.8 | 21.7 | 17.4 | 17.2 | 18.3 | 14.5 | 15.3 |
| Operating Income | -5.0 | 0.1 | -7.9 | 2.5 | 4.8 | -40.2 | 8.2 | 9.4 |
| Income Tax | -0.3 | 0.3 | 0.1 | 0.1 | 0.1 | -0.3 | 0.1 | 0.2 |
| Net Income | -4.2 | -1.4 | -8.4 | 2.0 | 3.9 | -0.0 | 0.0 | 0.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on CCLD: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| CCLD | $94M | 22.2× | 6.6× | 0.8× | 8.7% | — | 9.0% | 18.1% | 18.1% | — | 72 |
Peers = companies sharing CCLD's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.